Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael Stephen Pacey is active.

Publication


Featured researches published by Michael Stephen Pacey.


Bioorganic & Medicinal Chemistry | 2000

Avermectins and flea control : Structure-activity relationships and the selection of selamectin for development as an endectocide for companion animals

B.J. Banks; Bernard Frank Bishop; Nigel A. Evans; Stephen Paul Gibson; A.C. Goudie; K.A.F. Gration; Michael Stephen Pacey; D.A. Perry; M.J. Witty

Evaluation of a wide range of avermectin derivatives for flea activity in an in vitro feeding screen using the cat flea, Ctenocephalides felis, revealed a narrow structure-activity relationship (SAR) with activity surprisingly associated with monosaccharides and especially their C-5-oximes. We discovered commercially exploitable flea activity in a single compound, selamectin 33, which also possessed the necessary antiparasitic spectrum and margin of safety for development as a broad-spectrum companion animal endectocide.


The Journal of Antibiotics | 1992

C-13β-ACYLOXYMILBEMYCINS, A NEW FAMILY OF MACROLIDES

Mark A. Maxell; Bernard Frank Bishop; Patricia Bryce; Kenneth A. F. Oration; Hamida Kara; Robert A. Monday; Michael Stephen Pacey; David Austen Perry; Yasuhiro Kojima; Hiroshi Maeda; Satoshi Nishiyama; Junsuke Tone; Liang H. Huang

A family of novel milbemycins possessing C-13 beta-acyloxy substitution was produced by Streptomyces hygroscopicus ATCC 53718. These compounds were detected by HPLC diode array analysis and possess anthelmintic and ectoparasiticidal activity. The origin of the oxygen atom at C-13 is discussed.


The Journal of Antibiotics | 1991

Novel avermectins produced by mutational biosynthesis.

Christopher J. Dutton; Stephen Paul Gibson; Alexander Crossan Goudie; Kelvin Scott Holdom; Michael Stephen Pacey; John C. Ruddock; John D. Bu'Lock; Michelle Richards


Archive | 1994

New antiparasitic agents related to the milbemycins and avermectins

Bernard Frank Bishop; Michael Stephen Pacey; David Austen Perry


Archive | 1997

Erythromycins and process for their preparation

Peter Francis Leadlay; James Staunton; Jesus Cortes; Michael Stephen Pacey


The Journal of Antibiotics | 1998

Novel Erythromycins from a Recombinant Saccharopolyspora erythraea Strain NRRL 2338 pIG1 I. Fermentation, Isolation and Biological Activity

Michael Stephen Pacey; John P. Dirlam; Roderick W. Geldart; Peter F. Leadlay; Hamish McArthur; Ellen McCormick; Robert A. Monday; Thomas N. O'Connell; James Staunton; Toby Winchester


Archive | 2001

Treatment of rumen acidosis with α-amylase inhibitors

Bernard Joseph Banks; Mark Andrew Haxell; Graham Lunn; Michael Stephen Pacey; Lee R. Roberts


The Journal of Antibiotics | 1999

Structural elucidation of a novel erythromycin, 13-cyclopentyl-13-desethyl-erythromycin B, from a recombinant Saccharopolyspora erythraea strain, NRRL 2338 pIG/1.

Ian Parsons; Jeremy R. Everett; Michael Stephen Pacey; John C. Ruddock; Alistair G. Swanson; Christine Thompson


The Journal of Antibiotics | 2000

Preparation of 13-epi-selamectin by biotransformation using a blocked mutant of Streptomyces avermitilis.

Michael Stephen Pacey; Christopher J. Dutton; Robert A. Monday; John C. Ruddock; Graham Smith


Archive | 2001

N-(Isoxazol-5-yl)-sulfonamide derivatives and their use as endothelin antagonists

Bernard Joseph Banks; Nathan Anthony Logan Chubb; James John Eshelby; Michael Stephen Pacey; Darren John Schulz

Collaboration


Dive into the Michael Stephen Pacey's collaboration.

Researchain Logo
Decentralizing Knowledge